HCA Healthcare (HCA)
Market Price (12/29/2025): $477.22 | Market Cap: $114.1 BilSector: Health Care | Industry: Health Care Facilities
HCA Healthcare (HCA)
Market Price (12/29/2025): $477.22Market Cap: $114.1 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.8%, FCF Yield is 6.4% | Key risksHCA key risks include [1] multi-year payer mix pressure from Exchanges in 2026 and [2] Provider Tax pressure in 2028 and beyond. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%, CFO LTM is 12 Bil, FCF LTM is 7.3 Bil | |
| Low stock price volatilityVol 12M is 27% | |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include AI in Healthcare Management, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.8%, FCF Yield is 6.4% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%, CFO LTM is 12 Bil, FCF LTM is 7.3 Bil |
| Low stock price volatilityVol 12M is 27% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include AI in Healthcare Management, Show more. |
| Key risksHCA key risks include [1] multi-year payer mix pressure from Exchanges in 2026 and [2] Provider Tax pressure in 2028 and beyond. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Strong Fourth Quarter 2024 Financial Results: HCA Healthcare reported robust financial and operating results for the fourth quarter ended December 31, 2024. Revenues totaled $18.285 billion, an increase from the prior year, and same-facility admissions and equivalent admissions saw increases of 3.0% and 3.1% respectively. Adjusted EBITDA also showed an increase, reaching $3.712 billion compared to $3.618 billion in the fourth quarter of 2023.
2. Upbeat 2025 Guidance and Outlook: The company provided an optimistic forecast for 2025, projecting revenues between $72.8 billion and $75.8 billion and diluted earnings per share between $24.05 and $25.85. The midpoint of this EPS guidance surpassed the current analyst consensus, signaling strong future prospects.
Show more
Stock Movement Drivers
Fundamental Drivers
The 14.0% change in HCA stock from 9/28/2025 to 12/28/2025 was primarily driven by a 14.0% change in the company's P/E Multiple.| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 418.46 | 477.13 | 14.02% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 72698.00 | 72698.00 | 0.00% |
| Net Income Margin (%) | 8.21% | 8.21% | 0.00% |
| P/E Multiple | 16.76 | 19.11 | 14.02% |
| Shares Outstanding (Mil) | 239.17 | 239.17 | 0.00% |
| Cumulative Contribution | 14.02% |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| HCA | 14.0% | |
| Market (SPY) | 4.3% | 7.9% |
| Sector (XLV) | 15.2% | 26.4% |
Fundamental Drivers
The 26.2% change in HCA stock from 6/29/2025 to 12/28/2025 was primarily driven by a 18.3% change in the company's P/E Multiple.| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 378.06 | 477.13 | 26.20% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 71585.00 | 72698.00 | 1.55% |
| Net Income Margin (%) | 8.07% | 8.21% | 1.74% |
| P/E Multiple | 16.15 | 19.11 | 18.31% |
| Shares Outstanding (Mil) | 246.94 | 239.17 | 3.14% |
| Cumulative Contribution | 26.08% |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| HCA | 26.2% | |
| Market (SPY) | 12.6% | 6.5% |
| Sector (XLV) | 17.0% | 21.4% |
Fundamental Drivers
The 58.9% change in HCA stock from 12/28/2024 to 12/28/2025 was primarily driven by a 47.0% change in the company's P/E Multiple.| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 300.27 | 477.13 | 58.90% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 69621.00 | 72698.00 | 4.42% |
| Net Income Margin (%) | 8.52% | 8.21% | -3.55% |
| P/E Multiple | 13.00 | 19.11 | 46.97% |
| Shares Outstanding (Mil) | 256.76 | 239.17 | 6.85% |
| Cumulative Contribution | 58.16% |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| HCA | 58.9% | |
| Market (SPY) | 17.0% | 18.9% |
| Sector (XLV) | 13.8% | 36.8% |
Fundamental Drivers
The 103.4% change in HCA stock from 12/29/2022 to 12/28/2025 was primarily driven by a 53.2% change in the company's P/E Multiple.| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 234.59 | 477.13 | 103.39% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 59800.00 | 72698.00 | 21.57% |
| Net Income Margin (%) | 8.99% | 8.21% | -8.64% |
| P/E Multiple | 12.48 | 19.11 | 53.16% |
| Shares Outstanding (Mil) | 285.96 | 239.17 | 16.36% |
| Cumulative Contribution | 97.94% |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| HCA | 79.0% | |
| Market (SPY) | 48.4% | 20.3% |
| Sector (XLV) | 17.8% | 36.8% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HCA Return | 12% | 58% | -6% | 14% | 12% | 59% | 237% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| HCA Win Rate | 42% | 67% | 50% | 58% | 58% | 67% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| HCA Max Drawdown | -54% | -5% | -35% | -7% | 0% | -1% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See HCA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | HCA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -39.7% | -25.4% |
| % Gain to Breakeven | 65.8% | 34.1% |
| Time to Breakeven | 289 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -54.9% | -33.9% |
| % Gain to Breakeven | 121.7% | 51.3% |
| Time to Breakeven | 237 days | 148 days |
| 2018 Correction | ||
| % Loss | -23.4% | -19.8% |
| % Gain to Breakeven | 30.6% | 24.7% |
| Time to Breakeven | 247 days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
HCA Healthcare's stock fell -39.7% during the 2022 Inflation Shock from a high on 4/20/2022. A -39.7% loss requires a 65.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Analogy 1: Marriott for hospitals
Analogy 2: The Hilton of healthcare facilities
AI Analysis | Feedback
- Acute Care Hospital Services: Provides comprehensive medical, surgical, and emergency care within their network of hospitals.
- Outpatient and Ambulatory Services: Encompasses a variety of non-hospital settings including freestanding emergency rooms, urgent care centers, surgical centers, imaging centers, and physician clinics.
- Behavioral Health Services: Offers specialized treatment programs for mental health and substance use disorders.
- Rehabilitation Services: Delivers physical, occupational, and speech therapy aimed at recovery and improving functional abilities.
AI Analysis | Feedback
HCA Healthcare (NYSE: HCA) primarily sells its healthcare services to individuals.
The major categories of customers (patients) it serves, based on their primary payer source, include:
- Patients with Commercial Insurance: These individuals have healthcare coverage through private insurance companies. HCA Healthcare contracts with a wide range of commercial insurers (such as UnitedHealthcare, Aetna, Cigna, and Elevance Health) to provide medical services to their members.
- Patients Covered by Government Programs: This category includes individuals whose healthcare costs are primarily financed by government-sponsored programs. Key examples are Medicare (serving those aged 65 and older, and certain younger people with disabilities), Medicaid (for low-income individuals and families), and TRICARE (for military personnel and their families).
- Self-Pay Patients: These are individuals who are either uninsured or choose to pay for their medical services directly out-of-pocket, without the involvement of a third-party payer for the primary coverage.
AI Analysis | Feedback
- McKesson Corporation (MCK)
- Cardinal Health, Inc. (CAH)
- Johnson & Johnson (JNJ)
- Medtronic plc (MDT)
- Baxter International Inc. (BAX)
- Stryker Corporation (SYK)
- GE HealthCare Technologies Inc. (GEHC)
AI Analysis | Feedback
Samuel N. Hazen, Chief Executive Officer
Samuel N. Hazen is the Chief Executive Officer of HCA Healthcare, a position he assumed on January 1, 2019. He is a veteran of HCA Healthcare, having served the company for over 40 years. Prior to his CEO appointment, Hazen was president and chief operating officer since 2016. He has held various senior leadership positions within HCA, including president of operations (2011-2015) and president of HCA Healthcare's Western Group (2001-2010), where he was also its chief financial officer. Hazen began his career in 1983 in Humana's Financial Management Specialist program and has served as chief financial officer for hospitals in Georgia and Las Vegas. He serves on the boards of the Nashville Health Care Council, the Federation of American Hospitals, and the HCA Healthcare Foundation.
William B. Rutherford, Executive Vice President and Chief Financial Officer
William B. Rutherford serves as Executive Vice President and Chief Financial Officer of HCA Healthcare. He is a long-standing member of the HCA team, having joined as a staff auditor in 1986. Rutherford's roles at HCA have included Director of Operations Support and Chief Financial Officer for the Georgia Division, and Chief Financial Officer for the Eastern Group (1996-2005). In 2005, Rutherford left HCA to start his own training and education company, which also led to work with several private equity ventures. He also served as Chief Operating Officer of Psychiatric Solutions, a behavioral health services provider, from January 2006 to June 2007. Rutherford rejoined HCA in December 2008 as Chief Financial Officer of the Outpatient Services Group and later served as Chief Operating Officer of the Clinical and Physician Services Group before his appointment as CFO. He is a Certified Public Accountant.
Jon M. Foster, Executive Vice President and Chief Operating Officer
Jon M. Foster is the Executive Vice President and Chief Operating Officer of HCA Healthcare, a role he assumed on January 1, 2023. A 22-year veteran of HCA Healthcare, he previously served as president of HCA Healthcare's American Group since 2011. Prior to that, he was president and CEO of St. David's HealthCare in Austin, Texas, and executive vice president of operations for the Baptist Health System of East Tennessee. His career in healthcare began in 1986 at the Methodist Healthcare System in Houston, Texas.
Joseph A. Sowell, III, Senior Vice President and Chief Development Officer
Joseph A. Sowell, III is the Senior Vice President and Chief Development Officer for HCA Healthcare, joining the company on December 1, 2009. In this role, he is responsible for all development functions and transactions, including mergers, acquisitions, divestitures, and real estate involving hospitals, outpatient centers, and physician practices. Before joining HCA, Sowell was a partner at Waller Lansden Dortch & Davis, where his practice focused on healthcare law, mergers and acquisitions, joint ventures, private equity financing, tax law, and general corporate law. He also co-managed the firm's Corporate and Commercial Transactions practice. Earlier in his career, Sowell served as the head of development and later as chief operating officer of a healthcare company focused on developing comprehensive ambulatory care centers.
Michael S. Cuffe, M.D., M.B.A., Executive Vice President and Chief Clinical Officer
Dr. Michael S. Cuffe is the Executive Vice President and Chief Clinical Officer of HCA Healthcare, a position he has held since January 1, 2022. In this role, he is responsible for the company's clinical agenda, including clinical quality, nursing, care transformation, clinical informatics, and he continues to lead physician services, which includes urgent care operations, graduate medical education, and laboratory services. Dr. Cuffe joined HCA Healthcare in October 2011 as president and CEO of Physician Services. Prior to his time at HCA, he served as vice president for Ambulatory Services and Chief Medical Officer for Duke University Health System. He also held various leadership roles within the Duke Clinical Research Institute and served as Vice Dean for the Duke University School of Medicine. Dr. Cuffe received his MD and MBA degrees from Duke University.
AI Analysis | Feedback
The key risks to HCA Healthcare (HCA) include changes in payer mix and regulatory pressures, labor shortages and rising labor costs, and cybersecurity incidents.
- Payer Mix and Regulatory Pressures: HCA Healthcare faces significant risks from potential multi-year payer mix pressures, specifically "Exchange pressure in 2026 and Provider Tax pressure in 2028 and beyond". Changes in healthcare policies and regulations, such as those affecting Medicare and Medicaid reimbursement rates and overall healthcare reform, could adversely impact the company's operations and profitability.
- Labor Shortages and Rising Labor Costs: The company faces operational risks due to competition for staffing, particularly experienced nurses and other healthcare professionals, which may lead to increased labor costs and affect operations. These "stubborn labor and supply cost pressures" are considered a challenge to HCA's financial performance.
- Cybersecurity Incidents: Cybersecurity incidents pose a significant risk to HCA Healthcare, with potential impacts on operations, patient safety, and legal liabilities. The company has implemented security measures but acknowledges vulnerabilities to advanced cyber threats.
AI Analysis | Feedback
The aggressive expansion and vertical integration of non-traditional healthcare providers represent a clear emerging threat. Large retail chains, technology giants, and payer-owned organizations are increasingly entering and expanding their footprint in healthcare delivery, particularly in primary care, urgent care, and specialized outpatient services.
Examples include:
- Amazon: Acquired One Medical (primary care) and has been expanding its Amazon Pharmacy and virtual care offerings.
- CVS Health: Beyond its MinuteClinic network, CVS has acquired Signify Health (home health and value-based care enabler) and has invested heavily in its HealthHUBs model, co-locating primary care with pharmacy services. They are also actively acquiring primary care groups like Oak Street Health.
- Walgreens Boots Alliance: Has made significant investments in VillageMD, integrating primary care clinics within or adjacent to its pharmacies, and expanding into specialty pharmacy services with Shields Health Solutions.
- UnitedHealth Group (Optum): As one of the largest employers of physicians in the U.S., Optum continues to acquire physician groups, urgent care centers, and specialty clinics, building out a comprehensive care delivery network often focused on value-based care models.
- Walmart: Expanding its Walmart Health centers offering primary care, dental, behavioral health, and lab services.
These entities are establishing broad networks that compete directly with HCA's outpatient facilities and emergency rooms for patient volumes, especially for lower-acuity conditions and routine care. Their models often prioritize convenience, technology integration (telehealth, digital tools), and potentially lower costs, which can attract patients away from traditional hospital systems. This trend challenges HCA's traditional fee-for-service revenue streams and ability to capture patients across the care continuum.
AI Analysis | Feedback
HCA Healthcare (symbol: HCA) primarily operates in hospital and outpatient/ambulatory healthcare services in the United States and the United Kingdom. The addressable markets for their main products and services are as follows:
-
U.S. Hospital Services Market: The U.S. hospital services market was valued at approximately USD 2.48 trillion in 2024 and is projected to reach around USD 4.02 trillion by 2034, demonstrating a compound annual growth rate (CAGR) of 6.69% from 2025 to 2034. Another estimate placed the market at USD 2.32 trillion in 2023, with a projection to reach USD 3.79 trillion by 2033, growing at a CAGR of 4.85% from 2024 to 2033. In 2024, the U.S. hospital services market generated a revenue of USD 1.6014973 trillion and is expected to reach USD 2.0535116 trillion by 2030, with a CAGR of 4.2% from 2025 to 2030.
-
U.S. Outpatient/Ambulatory Services Market: The U.S. ambulatory services market size was estimated at USD 289.5 billion in 2023 and is projected to grow at a CAGR of 5.38% from 2024 to 2030. Outpatient volumes in the U.S. are expected to grow by 10.6% over the next five years.
-
Global Hospital Services Market: The global hospital services market size was estimated at USD 13.30 trillion in 2024 and is predicted to increase to approximately USD 24.17 trillion by 2034, expanding at a CAGR of 5.99% from 2025 to 2034.
-
Global Outpatient Care Market: The global outpatient care market size is expected to be worth around USD 150.7 billion by 2034, from USD 48.1 billion in 2024, growing at a CAGR of 12.1%.
AI Analysis | Feedback
HCA Healthcare (HCA) is expected to drive future revenue growth over the next 2-3 years through several key factors:
- Growth in Patient Volumes: HCA Healthcare consistently highlights broad-based volume growth across its markets and service lines as a primary revenue driver. This includes increases in same-facility admissions, equivalent admissions, and emergency room visits, reflecting strong demand for healthcare services, demographic trends, and the company's expanding service offerings. For instance, Q3 2025 saw 9.6% revenue growth driven by volume growth, and Q1 2024 reported a notable rise in same-facility admissions, emergency room visits, and outpatient surgeries.
- Favorable Payer Mix and Increased Patient Acuity: The company benefits from an improved payer mix, with a higher proportion of commercial volumes, and an increase in the acuity levels of its inpatient business. These factors lead to higher revenue per equivalent admission. For example, in Q1 2024, payer mix and acuity levels improved, with commercial volumes representing approximately 36% of equivalent admissions, up from 34% in the prior year.
- Strategic Network Development and Facility Expansion: HCA Healthcare is making significant capital investments to enhance its market position, expand its physical footprint, and increase capacity. This includes adding inpatient beds and developing new outpatient facilities, aiming to expand sites of care and improve access across its networks. HCA anticipates spending approximately $5 billion on capital expenditures for 2025, reflecting ongoing investment in infrastructure and services.
- Price Increases and Improved Reimbursement: HCA's revenue growth is also supported by higher reimbursement rates per equivalent admission. This indicates the company's ability to negotiate favorable pricing with payers and realize increased revenue from the services provided. In Q1 2024, same-facility revenue growth was a result of volume metrics coupled with 3.5% higher reimbursement per equivalent admission.
AI Analysis | Feedback
Capital Allocation Decisions of HCA Healthcare (HCA) (Last 3-5 Years)
Share Repurchases
- HCA Healthcare's Board of Directors authorized an additional share repurchase program for up to $10 billion of the company's outstanding common stock, with no specified time limit.
- In the third quarter of 2025, HCA repurchased 6.514 million shares of common stock at a cost of $2.498 billion.
- During the fourth quarter of 2024, the company repurchased 4.739 million shares for $1.700 billion.
Outbound Investments
- HCA Healthcare spent $635 million on acquisitions in 2023, which included $229 million for four hospital facilities in Texas and $406 million for non-hospital healthcare entities.
- In the first quarter of 2023, HCA acquired 90% of Valesco in a joint venture with Envision Healthcare.
- In the first quarter of 2025, HCA finalized the acquisitions of Catholic Medical Center in New Hampshire and Lehigh Medical Center in Florida for $227 million.
Capital Expenditures
- HCA Healthcare's capital expenditures were approximately $4.7 billion in 2023.
- Expected capital expenditures for 2024 are estimated to be around $5 billion.
- For 2025, capital spending is projected to be between $5.0 billion and $5.2 billion, with a focus on upgrading facilities, technology, and service offerings, and expanding inpatient and outpatient capacity to meet growing demand. The company has approximately $6 billion worth of projects under development.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to HCA. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
| 09302022 | HCA | HCA Healthcare | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 44.1% | 35.1% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for HCA Healthcare
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 175.78 |
| Mkt Cap | 199.5 |
| Rev LTM | 61,549 |
| Op Inc LTM | 11,311 |
| FCF LTM | 9,573 |
| FCF 3Y Avg | 8,728 |
| CFO LTM | 12,709 |
| CFO 3Y Avg | 11,974 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.2% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 16.4% |
| Op Mgn 3Y Avg | 15.7% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 18.5% |
| CFO/Rev 3Y Avg | 18.4% |
| FCF/Rev LTM | 14.1% |
| FCF/Rev 3Y Avg | 13.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 199.5 |
| P/S | 3.0 |
| P/EBIT | 21.2 |
| P/E | 33.0 |
| P/CFO | 16.2 |
| Total Yield | 5.2% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 6.2% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.5% |
| 3M Rtn | 7.5% |
| 6M Rtn | 20.7% |
| 12M Rtn | 25.3% |
| 3Y Rtn | 91.5% |
| 1M Excs Rtn | -3.0% |
| 3M Excs Rtn | 3.2% |
| 6M Excs Rtn | 8.5% |
| 12M Excs Rtn | 9.6% |
| 3Y Excs Rtn | 11.3% |
Comparison Analyses
Price Behavior
| Market Price | $477.13 | |
| Market Cap ($ Bil) | 111.1 | |
| First Trading Date | 03/10/2011 | |
| Distance from 52W High | -7.4% | |
| 50 Days | 200 Days | |
| DMA Price | $472.23 | $397.68 |
| DMA Trend | up | up |
| Distance from DMA | 1.0% | 20.0% |
| 3M | 1YR | |
| Volatility | 24.8% | 27.4% |
| Downside Capture | -10.88 | -10.54 |
| Upside Capture | 54.39 | 36.86 |
| Correlation (SPY) | 8.9% | 19.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.10 | 0.27 | 0.24 | 0.18 | 0.30 | 0.47 |
| Up Beta | -0.55 | 0.10 | 0.56 | 1.10 | 0.36 | 0.46 |
| Down Beta | 0.12 | 0.41 | 0.40 | 0.37 | 0.42 | 0.38 |
| Up Capture | 111% | 99% | 76% | 23% | 30% | 31% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 12 | 24 | 38 | 77 | 145 | 425 |
| Down Capture | -25% | -32% | -58% | -94% | -8% | 69% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 7 | 17 | 24 | 48 | 103 | 324 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of HCA With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| HCA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 58.3% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 27.2% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 1.66 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 36.9% | 19.2% | -4.9% | 0.0% | 33.2% | -10.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of HCA With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| HCA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 24.8% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 29.3% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.79 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 47.4% | 41.5% | 7.6% | 10.6% | 43.6% | 9.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of HCA With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| HCA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 23.0% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 32.4% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.72 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 51.3% | 51.3% | 2.2% | 22.2% | 50.6% | 11.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/24/2025 | 1.6% | 6.1% | 11.6% |
| 7/25/2025 | -2.1% | 3.7% | 18.6% |
| 4/25/2025 | -4.0% | 0.5% | 10.3% |
| 1/24/2025 | -3.8% | 2.8% | -1.8% |
| 10/25/2024 | -8.9% | -10.1% | -18.5% |
| 7/23/2024 | 4.5% | 10.2% | 15.3% |
| 4/26/2024 | -2.4% | -1.7% | 1.5% |
| 1/30/2024 | 5.2% | 8.3% | 8.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 19 | 17 |
| # Negative | 14 | 6 | 8 |
| Median Positive | 4.5% | 4.4% | 9.5% |
| Median Negative | -3.9% | -5.9% | -7.0% |
| Max Positive | 14.4% | 15.7% | 21.7% |
| Max Negative | -21.8% | -18.7% | -24.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10302025 | 10-Q 9/30/2025 |
| 6302025 | 8042025 | 10-Q 6/30/2025 |
| 3312025 | 5012025 | 10-Q 3/31/2025 |
| 12312024 | 2142025 | 10-K 12/31/2024 |
| 9302024 | 10312024 | 10-Q 9/30/2024 |
| 6302024 | 7292024 | 10-Q 6/30/2024 |
| 3312024 | 5022024 | 10-Q 3/31/2024 |
| 12312023 | 2162024 | 10-K 12/31/2023 |
| 9302023 | 10262023 | 10-Q 9/30/2023 |
| 6302023 | 8022023 | 10-Q 6/30/2023 |
| 3312023 | 4272023 | 10-Q 3/31/2023 |
| 12312022 | 2172023 | 10-K 12/31/2022 |
| 9302022 | 11012022 | 10-Q 9/30/2022 |
| 6302022 | 8012022 | 10-Q 6/30/2022 |
| 3312022 | 5032022 | 10-Q 3/31/2022 |
| 12312021 | 2182022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.